Sanofi’s Synthorx turkey comes home to roost
A takeover symbolising the push to beef up Sanofi’s oncology pipeline is taken back to the drawing board.
In a bear market it’s the bad news that matters
The market’s reaction to positive clinical data has largely held up through the downturn, but failures have really, really hurt.
Nektar and Puretech make strange bedfellows
It is hard to see a combination of the two businesses as much beyond a defensive move in troubled times.
Cytokine players keep the faith
The demise of Nektar’s bempegaldesleukin has not stemmed the tidal wave of companies developing IL-2 and IL-15 therapies.
Abbvie takes its Treg cue
The big pharma becomes the latest to look at IL-2 to harness regulatory T cells, but plenty of others have the same idea.
Biotech catalysts on the horizon
The second quarter should bring pivotal data for Karuna and key cardiomyopathy results for Alnylam, while Ionis's eplontersen lags in amyloidosis.
